April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Resonance Raman Spectroscopic Measurement of Macular Carotenoids in Best’s Disease
Author Affiliations & Notes
  • C. Brue
    Clinica Oculistica, Unversita Ancona, NEW YORK, New York
  • A. Giovannini
    Clinica Oculistica, Unversita Ancona, Acona, Italy
  • S. Salvolini
    Clinica Oculistica, Unversita Ancona, Ancona, Italy
  • C. Mariotti
    Clinica Oculistica, Unversita Ancona, Ancona, Italy
  • Footnotes
    Commercial Relationships  C. Brue, None; A. Giovannini, None; S. Salvolini, None; C. Mariotti, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1718. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Brue, A. Giovannini, S. Salvolini, C. Mariotti; Resonance Raman Spectroscopic Measurement of Macular Carotenoids in Best’s Disease. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1718.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Best’s disease (BD) is an autosomal dominantly inherited disorder with variable penetrance, that primarly affects the RPE. The retinopathy is caracterized by the variable deposition of yellowish material, attributed to lipofucsin in the retinal pigment epithelium (RPE). The phenotypic appearance varies with the stage of the disease.Light-adsorbing macular carotenoids (MCs),i.e. lutein and zeaxantin, are efficient free radical scavengers in human retina and might play a role in the wellness of the RPE in BD. The present study aimed at verifying whether MCs levels correlate with the stages of progression of the disease and if they can be predictive of subsequent visual outcome.

Methods: : We examined retrospectively 30 consecutive eyes of 30 patients of 30-50 years old (mean age 45.6 years) that were divided in four matched groups: i) control (negative for BD, n=6); and ii) BD group (n=6) in the vitelliform stage, (n=6) in the pseudoypopion stage, (n=6) in the scrambled-egg stage and (n=6) in the atrophic stage. All patients underwent fluorescein angiography, visual field and the electrooculogram. The levels of MCs were measured by a resonance Raman spectroscope in all of the subjects. Both the eyes of each subject were monitored and triplicate measurements were performed at each time. Moreover, pupil dilatation, instrument self-adjustment and appropriate eyeglasses correction were used.

Results: : MCs levels, measured as Raman counts, were 1990 (250), 1730 (205), 1800 (300), 1600 (270), 1370 (220) in the control, vitelliform, pseudoypopion, scrambled-egg and atrophic group respectively. The difference among the groups was statistically significant ( p<0.05).

Conclusions: : A role of MCs in the pathogenesis and stages of Best disease is proposed herein and future investigations are warranted to further clarify these aspects and to test their possible clinical use in the treatment of this pathology.

Keywords: macular pigment • macula/fovea • degenerations/dystrophies 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.